DexCom, Inc. (DXCM) Given Consensus Rating of “Hold” by Brokerages

DexCom, Inc. (NASDAQ:DXCM) has been given an average rating of “Hold” by the twenty-five ratings firms that are presently covering the company, Marketbeat reports. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and fourteen have issued a buy rating on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $69.69.

Several research firms recently weighed in on DXCM. ValuEngine cut DexCom from a “hold” rating to a “sell” rating in a report on Thursday. BidaskClub lowered DexCom from a “strong-buy” rating to a “buy” rating in a research note on Friday, December 22nd. Barclays restated a “hold” rating and set a $60.00 price objective on shares of DexCom in a research note on Monday, January 8th. Northland Securities restated a “hold” rating and set a $50.00 price objective on shares of DexCom in a research note on Thursday, November 2nd. Finally, BMO Capital Markets raised their price objective on DexCom to $74.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 12th.

Shares of DexCom (NASDAQ:DXCM) opened at $54.52 on Friday. The company has a debt-to-equity ratio of 0.84, a current ratio of 5.86 and a quick ratio of 5.50. DexCom has a fifty-two week low of $42.62 and a fifty-two week high of $86.32.

In other news, EVP Andrew K. Balo sold 6,490 shares of DexCom stock in a transaction on Wednesday, November 29th. The stock was sold at an average price of $60.00, for a total value of $389,400.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Kevin R. Sayer sold 12,000 shares of DexCom stock in a transaction on Monday, November 20th. The shares were sold at an average price of $55.00, for a total value of $660,000.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 48,140 shares of company stock worth $2,743,281. Corporate insiders own 1.70% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of the company. D.A. Davidson & CO. bought a new position in shares of DexCom in the 4th quarter valued at $208,000. Global X Management Co. LLC grew its position in DexCom by 56.3% during the 4th quarter. Global X Management Co. LLC now owns 62,063 shares of the medical device company’s stock worth $3,562,000 after acquiring an additional 22,362 shares during the last quarter. Wealthstreet Investment Advisors LLC bought a new stake in DexCom during the 4th quarter worth $473,000. OLD National Bancorp IN grew its position in DexCom by 103.8% during the 4th quarter. OLD National Bancorp IN now owns 20,311 shares of the medical device company’s stock worth $1,165,000 after acquiring an additional 10,345 shares during the last quarter. Finally, C WorldWide Group Holding A S grew its position in DexCom by 26.1% during the 4th quarter. C WorldWide Group Holding A S now owns 71,687 shares of the medical device company’s stock worth $4,114,000 after acquiring an additional 14,852 shares during the last quarter.

TRADEMARK VIOLATION WARNING: “DexCom, Inc. (DXCM) Given Consensus Rating of “Hold” by Brokerages” was first posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece can be read at https://www.americanbankingnews.com/2018/02/09/dexcom-inc-dxcm-given-consensus-rating-of-hold-by-brokerages.html.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply